NCT02381561 2026-03-19
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
National Cancer Institute (NCI)
Phase 1 Active not recruiting
National Cancer Institute (NCI)
Medical College of Wisconsin
Eli Lilly and Company
Pfizer
Pfizer
Accent Therapeutics